ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 100 mg/ml;  ;  ;   - solution for injection - 40 mg/0.4ml - active: adalimumab 100 mg/ml       excipient: mannitol polysorbate 80 water for injection - uveitis humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. humira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

abbvie limited - venetoclax 10mg;  ; venetoclax 50mg; venetoclax 100mg - film coated tablet - active: venetoclax 10mg   excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry ii yellow 85f32450 polysorbate 80 purified water sodium stearyl fumarate active: venetoclax 50mg excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry ii beige 85f97497 polysorbate 80 purified water sodium stearyl fumarate active: venetoclax 100mg excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry ii yellow 85f32450 polysorbate 80 purified water sodium stearyl fumarate - venclexta is indicated for the treatment of patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

abbvie limited - venetoclax 10mg;   - film coated tablet - 10 mg - active: venetoclax 10mg   excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry ii yellow 85f32450 polysorbate 80 purified water sodium stearyl fumarate - venclexta is indicated for the treatment of patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

abbvie limited - venetoclax 100mg;   - film coated tablet - 100 mg - active: venetoclax 100mg   excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry ii yellow 85f32450 polysorbate 80 purified water sodium stearyl fumarate - venclexta is indicated for the treatment of patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

abbvie limited - venetoclax 50mg;   - film coated tablet - 50 mg - active: venetoclax 50mg   excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry ii beige 85f97497 polysorbate 80 purified water sodium stearyl fumarate - venclexta is indicated for the treatment of patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

abbvie limited - ritonavir 100mg - film coated tablet - 100 mg - active: ritonavir 100mg excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry white 16b18449 sodium stearyl fumarate sorbitan laurate - norvir is indicated for use in combination with appropriate antiretroviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of hiv-1 infection in adults and children aged 12 years and older. for persons with advanced hiv disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and aids defining clinical events for patients who received ritonavir. median duration of follow-up in this study was 6 months. the clinical benefit from ritonavir for longer periods of treatment is unknown. for persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks duration.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

abbvie limited - ritonavir 80 mg/ml - oral solution - 80 mg/ml - active: ritonavir 80 mg/ml excipient: caramel citric acid ethanol peppermint oil polyoxyl 35 castor oil propylene glycol purified water saccharin sodium sunset yellow fcf - norvir is indicated for use in combination with appropriate antiretroviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of hiv-1 infection in adults and children aged 12 years and older. for persons with advanced hiv disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and aids defining clinical events for patients who received ritonavir. median duration of follow-up in this study was 6 months. the clinical benefit from ritonavir for longer periods of treatment is unknown. for persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks duration.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;   - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;  ; ribavirin 200mg;   - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 active: ribavirin 200mg   excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90614 povidone - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;  ; ribavirin 400mg;  ; ribavirin 600mg - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 active: ribavirin 400mg   excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90553 povidone active: ribavirin 600mg excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90623 povidone - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.